company background image
2GH logo

Merus DB:2GH Stock Report

Last Price

€42.20

Market Cap

€3.0b

7D

6.0%

1Y

3.4%

Updated

16 Mar, 2025

Data

Company Financials +

Merus N.V.

DB:2GH Stock Report

Market Cap: €3.0b

2GH Stock Overview

A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. More details

2GH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 83.5% below our estimate of its fair value

Revenue is forecast to grow 49.61% per year

Analysts in good agreement that stock price will rise by 83.4%

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Merus N.V. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€487.3m

Heidelberg Pharma

XTRA:HPHA

€121.2m

SCHOTT Pharma KGaA

XTRA:1SXP

€3.6b

Price History & Performance

Summary of share price highs, lows and changes for Merus
Historical stock prices
Current Share PriceUS$42.20
52 Week HighUS$55.50
52 Week LowUS$36.80
Beta1.15
1 Month Change12.23%
3 Month Change5.50%
1 Year Change3.43%
3 Year Change68.80%
5 Year Change287.16%
Change since IPO197.73%

Recent News & Updates

Recent updates

Shareholder Returns

2GHDE BiotechsDE Market
7D6.0%3.1%-0.5%
1Y3.4%-6.0%15.5%

Return vs Industry: 2GH exceeded the German Biotechs industry which returned -5.8% over the past year.

Return vs Market: 2GH underperformed the German Market which returned 15.5% over the past year.

Price Volatility

Is 2GH's price volatile compared to industry and market?
2GH volatility
2GH Average Weekly Movement6.2%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: 2GH has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 2GH's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003291Bill Lundbergwww.merus.nl

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

Merus N.V. Fundamentals Summary

How do Merus's earnings and revenue compare to its market cap?
2GH fundamental statistics
Market cap€2.99b
Earnings (TTM)-€197.86m
Revenue (TTM)€33.20m

90.1x

P/S Ratio

-15.1x

P/E Ratio

Is 2GH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2GH income statement (TTM)
RevenueUS$36.13m
Cost of RevenueUS$22.71m
Gross ProfitUS$13.42m
Other ExpensesUS$228.75m
Earnings-US$215.33m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.12
Gross Margin37.15%
Net Profit Margin-595.93%
Debt/Equity Ratio0%

How did 2GH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 04:48
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Merus N.V. is covered by 24 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBMO Capital Markets Equity Research
Evan SeigermanBMO Capital Markets Equity Research
Tazeen AhmadBofA Global Research